ASMB | Assembly Biosciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	17.66 - 19.20
52 Week Range	7.68 - 20.04
Beta	0.45
Implied Volatility	583.53%
IV Rank	91.01%
Day's Volume	29,243
Average Volume	16,070
Shares Outstanding	6,345,560
Market Cap	116,441,026
Sector	Healthcare
Industry	Biotechnology
IPO Date	2010-12-17

Valuation
Profitability
Growth
Health
P/E Ratio	-2.11
Forward P/E Ratio	N/A
EPS	-8.69
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	65
Country	USA
Website	ASMB

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

ASMB's peers: ACHL, ACHV, ALGS, ALLK, ALRN, APTO, ARWR, ASLN, SPRO, TIL, NLTX, CTMX, NUVB, NXTC, ATHA, BOLT, PMCB, CHRS, CKPT, CMRX, CNTB, CNTX, CRBP, CYCC, GLPG, GLYC, INDP, KOD, KPTI, KRON, KZIA, LBPH, LVTX, LYRA, MEIP, MTEM, MTNB, NKTR, NLSP, OCUL, ONCT, OVID, PRQR, PULM, QLGN, SPRC, SRZN, TBPH, WVE, QNCX, DOMH

*Chart delayed

Analyzing fundamentals for ASMB we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is on medium level and Health is weak. For more detailed analysis please see ASMB Fundamentals page.

Watching at ASMB technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on ASMB Technicals page.